clinical trials

Rosen Law Firm seeks lead plaintiffs in securities class action against Aldeyra Therapeutics over alleged reproxalap trial misstatements. Deadline: May 29, 2026.

Schall Law Firm seeks $ALDX investors for securities fraud lawsuit alleging Aldeyra Therapeutics made false reproxalap drug claims between November 2023-March 2026.

Clinical trials tech market projected to grow 59% from $51.15B (2025) to $81.46B (2030) at 9.8% CAGR, driven by AI, decentralized models, and digital transformation.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.

Orion posts strong Q1 with 17.8% revenue growth, 47.3% operating profit surge, and raises 2026 outlook. Pipeline advances boost investor confidence.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.

Ascentage Pharma selected for six abstracts at ASCO 2026, including three rapid oral presentations featuring data on three key oncology drug candidates.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Lawsuit filed against $CORT alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects, concealing regulatory concerns.

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Peptide drug conjugate market projected to reach $1.5 billion by 2031 with 14%+ CAGR, driven by targeted oncology therapies and innovative linker technologies from major biotech players.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.

Sutro Biopharma presented encouraging preclinical data for its ADC pipeline at AACR 2026, with lead candidate STRO-004 showing robust antitumor activity and plans for IND submissions in 2026.

Rosen Law Firm reminds $ALDX investors of May 29, 2026 deadline to join securities class action alleging false reproxalap trial disclosures.

Rosen Law Firm urges Corcept Therapeutics investors with losses exceeding $100K to join securities class action before April 21, 2026 deadline over alleged FDA application misrepresentations.

Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.